EARLY STAGE RESECTABLE LUNG CANCER;

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

Fred R. Hirsch, MD, PhD, FASCO Professor of Medicine and Pathology Executive Director, Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai Health System, New York.




Figure 4

POST-SURGICAL PROGNOSIS

IASLC 9th Edition Staging Project Overall Survival (OS) from the Date of Surgery Pathologic Post-Surgical 8th Edition TNM Stage Groupings NSCLC only

12



	Deaths / N	Median in Years	5-Year Estimate	100)% - -	
4	2102/18113	NR	88% (88, 89)	80)% -	
3	1684 / 7625	NR	77% (76, 78)	00	//0	
A	489 / 1634	NR	67% (65, 70)			
	1930 / 5400	7.6 (7, 8.3)	61% (60, 63)	~ 60)% -	۳ <u>ر</u> ۷
IA	2447 / 5202	4.9 (4.6, 5.2)	49% (48, 51)	(%)		۲ <u>ـــر</u>
IB	686 / 1165	2.9 (2.6, 3.2)	35% (31, 38)	so ,		1 L
IC	36 / 53	2.1 (1.3, 2.8)	19% (7, 32)	40)% -	

5-Year Survival:

IB-IIIA: 80%-50%

	c	J J		logic Third Stage Groupings			
	n=39,0	002; R ² =45.144		n=38,335; R ² =46.020			
Multivariable Cox Model	n/N (%)	HR (95% CI)	P-value	n/N (%)	HR (95% CI)	P-value	
IB (vs IA)	7,596/39,002 (19.48%)	1.87 (1.76-2.00)	<.0001	7,596/38,335 (19.81%)	1.87 (1.75-2.00)	<.0001	
IIA (vs IB)	1,623/39,002 (4.16%)	1.36 (1.23-1.51)	<.0001	2,819/38,335 (7.35%)	1.42 (1.30-1.54)	<.0001	
IIB (vs IIA)	5,372/39,002 (13.77%)	1.27 (1.15-1.41)	<.0001	4,176/38,335 (10.89%)	1.27 (1.17-1.38)	<.0001	
IIIA (vs IIB)	5,167/39,002 (13.25%)	1.56 (1.47-1.66)	<.0001	4,073/38,335 (10.62%)	1.45 (1.35-1.55)	<.0001	
IIIB (vs IIIA)	1,155/39,002 (2.96%)	1.51 (1.39-1.65)	<.0001	1,582/38,335 (4.13%)	1.69 (1.56-1.82)	<.0001	
IIIC (vs IIIB)	51/39,002 (0.13%)	1.78 (1.26-2.52)	0.0011	51/38,335 (0.13%)	1.67 (1.18-2.35)	0.0036	
Age 65 or Older (vs younger than 65)	21,842/39,002 (56.00%)	1.65 (1.58-1.72)	<.0001	21,520/38,335 (56.14%)	1.67 (1.59-1.74)	<.0001	
Female (vs Male)	20,188/39,002 (51.76%)	0.99 (0.95-1.03)	0.5274	19,860/38,335 (51.81%)	0.99 (0.95-1.03)	0.6735	
Europe (vs Asia)	4,280/39,002 (10.97%)	1.49 (1.40-1.59)	<.0001	4,227/38,335 (11.03%)	1.48 (1.39-1.57)	<.0001	
North America (vs Asia)	6,505/39,002 (16.68%)	1.51 (1.42-1.60)	<.0001	6,423/38,335 (16.75%)	1.52 (1.44-1.61)	<.0001	
Rest of World (vs Asia)	1,404/39,002 (3.60%)	1.54 (1.40-1.70)	<.0001	1,393/38,335 (3.63%)	1.53 (1.39-1.69)	<.0001	
Squamous (vs Non-squamous)	8,543/39,002 (21.90%)	1.43 (1.37-1.50)	<.0001	8,431/38,335 (21.99%)	1.47 (1.40-1.54)	<.0001	

IASLC 9th Edition Staging Project Overall Survival (OS) from the Date of Surgery Pathologic Post-Surgical 9th Edition TNM Stage Groupings NSCLC only




And then....CALGB 140503




Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer

Nasser Altorki, M.D., Xiaofei Wang, Ph.D, David Kozono, M.D., Ph.D., Colleen Watt, B.S., Rodney Landrenau, M.D., Dennis Wigle, M.D., Ph.D., Jeffrey Port, M.D., David R. Jones, M.D., Massimo Conti, M.D., Ahmad S. Ashrafi, M.D., Moishe Liberman, M.D., Ph.D., Kazuhiro Yasufuku, M.D., Ph.D., Stephen Yang, M.D., John D. Mitchell, M.D., Harvey Pass, M.D., Robert Keenan, M.D., Thomas Bauer, M.D., Daniel Miller, M.D., Leslie J. Kohman, M.D., Thomas E. Stinchcombe, M.D., and Everett Vokes, M.D.

Equivalent survival





CALGB 140503: Phase III randomized trial comparing lobectomy and sublobar resection for small-sized carcinoma

Suspected or confirmed peripheral NSCLC T1aN0 ≤ 2 cm


Stratification factors

- Tumor size (<1,1-15,1.6-2)
- Ever/never smokers
- · Squamous/adenocarcinoma

Important questions remain...

Subgroup	Sublobar Resection	Lobar Resection	Hazard Ratio for Disease Recurrence or Death (95% CI)						
	no. of po	patients							
Overall	340	357	-#-	1.03 (0.81-1.30)					
Age									
≤65 yr	123	131		0.96 (0.64-1.45)					
>65 yr	217	226		1.07 (0.80-1.42)					
Age						Disease	Recurrence		
≤70 yr	206	211		1.10 (0.80-1.52)		Disease r	<i>(ecurrence</i>		
>70 yr	134	146		0.94 (0.67-1.33)	4				
Sex				· · · · · · · · · · · · · · · · · · ·					
Male	150	147		1.12 (0.78-1.59)		Lobar	Sublobar	Total	D.M.
Female	190	210		0.97 (0.71-1.33)		N=351	N=336	N=687	P-Value
Tumor location						N=331	N-330	N-007	
Right upper lobe	120	128		1.00 (0.68-1.47)			[
Right middle lobe	19	16		► 2.27 (0.71-7.26)	Overall	103 (29.3%)	102 (30.4%)	205 (29.8%)	0.8364
Right lower lobe	55	43		0.83 (0.44-1.56)					
Left upper lobe	86	104		0.91 (0.59-1.41)	Locoregional		· · · · ·		
Left lower lobe	56	63		1.35 (0.69-2.64)		35 (10%)	45 (13.4%)	80 (11.6%)	0.2011
Lingula	4	3 —		→ 0.93 (0.15-5.71)	only				
Histologic type						1 7	· · · · · · · · · · · · · · · · · · ·		
Squamous-cell carcinoma	45	53		0.99 (0.54-1.79)	Regional only	9 (2.6%)	6 (1.8%)	15 (2.2%)	0.6623
Adenocarcinoma	218	226		1.09 (0.80-1.50)					
Other	77	78		0.93 (0.60-1.46)		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
Smoking status					Any Distant	59 (16.8%)	51 (15.2%)	110 (16.0%)	0.6323
Never	28	35		→ 1.75 (0.65-4.71)	Any Distant	00 (10.070)	01 (10.270)	110(10.070)	0.0020
Former	172	177		0.91 (0.65-1.27)					<u> </u>
Current	140	145		1.07 (0.75-1.52)					
Tumor size					4				
<1.0 cm	28	30		0.83 (0.29-2.40)	4				
1.0-1.5 cm	174	180		0.90 (0.65-1.25)					
>1.5-2.0 cm	138	147		1.24 (0.87-1.77)	Whyd	lo "early st	'aae" nati	ents fail v	with
ECOG performance-status score					vviiy u	o curry st	uge put	cincs juin v	VICII
0	263	250		0.96 (0.72-1.26)	1	1.	1	1	
1 or 2	77	107		1.31 (0.84-2.04)	distant	disease ar	nd can we	: better ar	etect
		0.2	0.2 0.4 0.6 1.0 1.6 2.7	· · · · · · · · · · · · · · · · · · ·					
		-	·	/		these	who will	21	

Where is wedge vs. segmentectomy?!




CALGB 140503 Segmentectomy = 129 (42%) Wedge = 200 (58%)

Sublobar Resection Better Lobar Resection Bette

those who will?!

Object of neo-adjuvant IO



Improvement in OS

Improvement in OS (NeoTORCH, KN671)

Improvement in OS (Other studies)

Pathologic complete response rates in randomized, phase III trials

Study	Neoadjuvant treatment	Sample Size #	% with PCR
Checkmate 816 ¹	CTx + Nivolumab x 3	358	24
Keynote 671 ²	CTx + Pembrolizumab x 4	797	18
NeoTorch ³	CTx + Toripalimab x 4	404	25
Aegean ⁴	Ctx + Durvalumab x 4	740	17
Checkmate 77T ⁵	Ctx + Nivolumab x 4	452	20
	~21		

1) Forde P et. al NEJM 2022. 2) Wakelee H et al NEJM 2023. 3) Lu S et. al ASCO plenary April 2023. 4). Heymach J et. al AACR 2023. 5) Cascone T et. al ESMO 2023.








a National Cancer Institute program A program of the N

A program of the National Cancer Institute of the National Institutes of Health


Pathologic complete response - a more promising surrogate endpoint



15	20	25	30	35	40	45	50	55	60


21	15	10	5	1	0	0	0	0	0
32	22	21	10	4	1	1	1	1	1

Depth of pathologic response: CM816




Forde et al NEJM 2022 Supplementary data

Presence of MRD is indicative of recurrence




Zhang JT, et al. Cancer Discov 2022;12(7):1690–1701

EFS of patients with no CPR from CM816 (Major + Less Than Major pathologic response)



Forde et al NEJM 2022

Insights from KN671



Pembrolizumab group, with major										
Placebo group, with major										
Pembrolizumab group, without major										
		ebo group, v athological	without major response							
).54 (95% (e. 0.73 (95		· · ·								
42	48	1 54								
1 2	0	0								
10	0	0								
7	1	0								

Wakelee et al NEJM 2023


To rephase the question on the role of adjuvant therapy

Should we give adjuvant therapy to patients with major pathologic response after neo-adjuvant chemo-IO?

Should we give adjuvant therapy to patients with less than major pathologic response after neo-adjuvant chemo-IO?


Can we use MRD to personalize adjuvant IO for patients with major or less than major pathologic response?

More adjuvant IO for MRD positive??




Why would you want to give more adjuvant immunotherapy if it didn't work well (in neo-adjuvant setting)

More adjuvant IO for MRD positive/negative??



How best to select patients for further adjuvant IO?

My humble proposal





Adjuvant IO x 1 year

Primary endpoint: OS

Placebo

Adjuvant ADC??

+

Adjuvant IO x 1 year


Primary endpoint: OS


Placebo

PROPOSAL:

INcorporating pathologic respon<u>S</u>e in patlents with early staGe lung cancer to optimize immunot<u>H</u>erapy in the adjuvan<u>T</u> setting (INSIGHT) – S2414

PI: Jeremy Cetnar Co-PI: Ray Osarogiagbon Statistician: Yingqi Zhao, Michael LeBlanc Lung Committee Chair: Jhanelle Gray Patient advocate: Judy Johnson Pathology committee: TBD QOL PI: TBD










A program of the National Cancer In of the National Institutes of Health

INSIGHT Schema – SWOG



Inclusion:

- ECOG 0/1
- R0 resection
- No known EGFR/ALK
- Confirmed PD-L1 status

Stratification factors:

- Stage (II v III)
- PD-L1 (<1% v ≥1%)
- Histology (Sq v NSq)

Exploratory Objectives

- AI based assessment
- ctDNA
- Central review





Durvalumab x 12 months

Surveillance



Follow-up evaluations:

- CT scan Q3 month yr 1
- QOL questionnaires

¹ Pts can enroll on optional pre-screening study





A program of the National Cancer Institute of the National Institutes of Health

THANKS, See you in NYC!

ELLIS FLER E ART IR44 10 Th 10 Th 10 Bener Sta 25 COLUMN STREET Parallel long balan E Liners able sail in

Bertlars Birsel 100 SUS LIVII - maunt HEFING INCLUDE SUM States TRefails CA PELLI

. ... CONTRACTOR OF CALIFORNIA

......



KIIIIII IIIII